The brain, traffic and nano-circuits -- e-Science takes on major challengesIssued by EPSRC on behalf of the UK e-Science Programme Research into three major scientific and technological challenges is to receive a major boost from the appli...

BioAxone Therapeutic announced todaythat it has completed its targeted patient enrollment of the Phase I/IIaNorth American clinical trial of Cethrin(R) for the treatment of acutespinal cord injury (SCI). Cethrin(R), a recombinant protein-b...

A protein once thought to be a principal player in linking nerve responses in the nose to those in the brain actually has a more specialized role, according to a Yale School of Medicine study published in Molecular and Cellular Neuroscienc...

Patients with Parkinson's disease who are undergoing a treatment known as deep brain stimulation may benefit from the direct involvement of a neurologist with expertise both in movement disorders and in deep brain stimulation, according to...

The NUBAC?Disc Arthroplasty device is made from PEEK-OPTIMA?which has established biocompatibility and great biodurability for spinal fusion implants. It incorporates a unique two-piece ball and socket, designed to achieve load sharing and...

Findings of a recent genetic study on developmental brain disorders may be the "tip of an iceberg" revealing factors involved with a number of congenital diseases, according to UC Irvine researchers. The study is the first to find that mut...

Two papers in the July 6, 2006, Neuron, published by Cell Press, report evidence that surprisingly simple genetic abnormalities in the machinery of critical neuronal growth-regulating molecules can kill neurons in Down's syndrome, Alzheime...

A winner of UniQuest's 2006 Trailblazer innovation competition, Dr Frederic Meunier, is developing a treatment for motoneuronal diseases based on modifying botox - the popular anti-wrinkle treatment. Motoneuronal diseases cause a degenerat...

Avicena Group, Inc.("Avicena"), a developer of novel pharmaceutical and therapeutic products,announced today that a Phase II clinical trial of two combination therapiesincorporating ALS-08, one of its proprietary drug candidates for thetre...

In preliminary results, researchers have shown that a drug which mimics the effects of the nerve-signaling chemical dopamine causes neurons to develop in the part of the brain where cells are lost in Parkinson's disease (PD). The drug...